Top Selling Monoclonal Antibodies 2014
47.1K views | +25 today
Follow
 
Scooped by Krishan Maggon
onto Top Selling Monoclonal Antibodies 2014
Scoop.it!

Killing Cancer Through the Immune System - UCSF

Killing Cancer Through the Immune System - UCSF | Top Selling Monoclonal Antibodies 2014 | Scoop.it
UCSF News Services
Killing Cancer Through the Immune System
UCSF News Services
...
Krishan Maggon 's insight:

The marketing success of Ipilimumab has started the immunotherapy of cancer era.

more...
Krishan Maggon 's curator insight, February 4, 2014 7:47 AM
Krishan Maggon 's insight:

The marketing success of Ipilimumab has started the immunotherapy of cancer era.

Gilbert C FAURE's curator insight, February 4, 2014 11:31 AM

obv

Top Selling Monoclonal Antibodies 2014
Top Selling Monoclonal Antibodies 2014
Abstract A review of the best selling monoclonal antibodies in 2014 and 2013 is provided. Humira with sales of over $12.7 billion ($9.3 bn in 2012, $11bn 2013) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2014 and since 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012-2013 Table.  Remicade (9.8 Bn), Rituxan (7.6 Bn) , Avastin (7.0 Bn) and Herceptin (6.8 Bn)  were the second, third, fourth and fifth top selling mabs in 2014. The actual sales for 2014 as reported by the companies are provided. The total sales of the top selling blockbuster mabs listed in the Table were $68 billion in 2014. The global sales of all the approved therapeutic monoclonal antibodies were $78 billion in 2014. Besides the top 5 mabs, there was two monoclonal antibody with sales of over $3 billions, three with sales over $ 2 billion and 6 with sales of over $ 1 billion in 2014. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 36 monoclonal antibodies are marketed in the US and Europe (January 2015).  FDA approved 6 new monoclonal antibodies in 2014. Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs and had sales of $2.2 billion in 2014.
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Best Selling Blockbuster Monoclonal Antibodies 2015

Best Selling Blockbuster Monoclonal Antibodies 2015 | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Abstract 

 A review of the best selling monoclonal antibodies in 2015 and previous years is provided. Humira with sales of over $14.5 billion ($9.3 bn in 2012, $11bn 2013, $12.7 billion in 2014) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2015. Humira has remained the top selling global brand since 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012-2013 Table. Remicade (8.8 Bn), Rituxan (7.7 Bn) , Avastin (7.5 Bn) and Herceptin (7.3 Bn) were the second, third, fourth and fifth top selling mabs in 2014. The actual sales for 2015 as reported by the companies are provided. The total sales of the top selling blockbuster mabs listed in the Table were $72 billion in 2015. The global sales of all the approved therapeutic monoclonal antibodies were $80 billion in 2015. Besides the top 5 mabs, there was one monoclonal antibody with sales of over $4 billions, six with sales over $ 2 billion and 5 with sales of over $ 1 billion in 2015. There were 17 blockbuster mabs in 2015. At least 3 new recently launched mabs are likely to cross sales of $ 1 billion in 2016.
Krishan Maggon 's insight:
No public access as the article is in preparation and not completed


Best Selling Monoclonal Antibodies 2015 by Krishan Maggon

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Repatha evolocumab Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016

New Repatha evolocumab Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016 | Top Selling Monoclonal Antibodies 2014 | Scoop.it
THOUSAND OAKS, Calif., Aug. 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data presented at the European Society of Cardiology (ESC) Congress 2016 showing Repatha® (evolocumab) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients across cardiovascular (CV) risk subgroups or with familial hypercholesterolemia (FH).

Researchers looking at the "Efficacy of evolocumab in patients across ESC/EAS CV risk subgroups," categorized a total of 2,532 patients from three, 12-week Phase 3 studies by the four ESC/European Atherosclerotic Society (EAS) risk criteria (very high, high, moderate and low). The analysis showed that treatment with Repatha 140 mg every two weeks or 420 mg monthly consistently reduced levels of LDL-C and other lipids from baseline to the mean of weeks 10 and 12 across all risk categories compared to placebo or ezetimibe controls. For example, among very high-risk patients, Repatha reduced LDL-C levels from baseline 65.2 percent more than placebo and 40.7 percent more than ezetimibe. The rates of overall adverse events were similar for the three groups, occurring in 43.1 percent, 50.5 percent and 40.8 percent of patients on Repatha, ezetimibe and placebo, respectively.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Blood Coagulation: Hemostasis

Blood Coagulation: Hemostasis | Top Selling Monoclonal Antibodies 2014 | Scoop.it
The blood coagulation page provides details of the normal processes of hemostasis and mechanisms for therapeutic intervention in abnormal bleeding
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Microscopy Academic Units | Medicine | University of Southampton

Microscopy Academic Units | Medicine | University of Southampton | Top Selling Monoclonal Antibodies 2014 | Scoop.it
The microscopy core facility provides a specialist microscopy service to the Unit as well as providing training and advice in microscopy techniques
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Official Full-Text Publication: CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis on ResearchGate, the professional network for scientists.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

BARDA Backs Antibody Therapy Against MERS Virus

BARDA Backs Antibody Therapy Against MERS Virus | Top Selling Monoclonal Antibodies 2014 | Scoop.it
BARDA will provide funding to Regeneron to support packaging and labeling of the antibodies for human use, and for Investigational New Drug application
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Research from JAMA — Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

Assuming 2015 prices, PCSK9 inhibitor use in patients with heterozygous FH or ASCVD did not meet generally acceptable incremental cost-effectiveness thresholds and was estimated to increase US health care costs substantially. Reducing annual drug prices from more than $14 000 to $4536 would be necessary to meet a $100 000 per QALY threshold.
Krishan Maggon 's insight:
Dhruv S. Kazi, MD, MSc, MS1,2,3,4,5; Andrew E. Moran, MD, MPH6,7; Pamela G. Coxson, PhD1,2,8; Joanne Penko, MS, MPH1,2; Daniel A. Ollendorf, PhD9; Steven D. Pearson, MD, MSc9; Jeffrey A. Tice, MD2; David Guzman, MSPH1; Kirsten Bibbins-Domingo, P

AMA. 2016;316(7):743-753. doi:10.1001/jama.2016.11004.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Data Add To Understanding Of Repatha Evolocumab In Multiple Patient Populations

New Data Add To Understanding Of Repatha Evolocumab In Multiple Patient Populations | Top Selling Monoclonal Antibodies 2014 | Scoop.it
THOUSAND OAKS, Calif., Aug. 22, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present 11 abstracts at the upcoming European Society of Cardiology (ESC) Congress 2016, being held Aug. 27-31 in Rome. 

 Abstracts include data evaluating Repatha® (evolocumab), a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for the treatment of patients with high cholesterol, across ESC/European Atherosclerosis Society (EAS) cardiovascular risk subgroups, as well as the long-term efficacy and safety of Repatha treatment in patients with the genetic condition heterozygous familial hypercholesterolemia (HeFH). Additionally, an analysis of familial hypercholesterolemia (FH) diagnosis and prevalence will be highlighted as a Rapid Fire Abstract.
Krishan Maggon 's insight:
Share your insight
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Human IgG4: a structural perspective - Davies - 2015 - Immunological Reviews - Wiley Online Library

Human IgG4: a structural perspective - Davies - 2015 - Immunological Reviews - Wiley Online Library | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Summary IgG4, the least represented human IgG subclass in serum, is an intriguing antibody with unique biological properties, such as the ability to undergo Fab-arm exchange and limit immune complex formation. The lack of effector functions, such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, is desirable for therapeutic purposes. IgG4 plays a protective role in allergy by acting as a blocking antibody, and inhibiting mast cell degranulation, but a deleterious role in malignant melanoma, by impeding IgG1-mediated anti-tumor immunity. These findings highlight the importance of understanding the interaction between IgG4 and Fcγ receptors. Despite a wealth of structural information for the IgG1 subclass, including complexes with Fcγ receptors, and structures for intact antibodies, high-resolution crystal structures were not reported for IgG4-Fc until recently. Here, we highlight some of the biological properties of human IgG4, and review the recent crystal structures of IgG4-Fc. We discuss the unexpected conformations adopted by functionally important Cγ2 domain loops, and speculate about potential implications for the interaction between IgG4 and FcγRs.
Krishan Maggon 's insight:
Davies, A. M. and Sutton, B. J. (2015), Human IgG4: a structural perspective. Immunol Rev, 268: 139–159. doi:10.1111/imr.12349
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The many faces of FcγRI: implications for therapeutic antibody function. - PubMed - NCBI

The many faces of FcγRI: implications for therapeutic antibody function. - PubMed - NCBI | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Immunol Rev. 2015 Nov;268(1):160-74. doi: 10.1111/imr.12334. Review

Summary Fcγ receptor I (FcγRI or CD64) is the sole human Fc receptor with high affinity for monovalent IgG. While it contains an immunoreceptor tyrosine-based activation motif in its cytoplasmic domain, binding of FcγRI can result in a complex array of activating and inhibitory outcomes. For instance, binding of monomeric IgG provides a low-intensity tonic signal through FcγRI that is necessary for full interferon γ receptor signaling in the same cell. Interaction of FcγRI with larger high-avidity complexes can result in phagocytosis, the generation of reactive oxygen species, as well as the synthesis and release of inflammatory cytokines.
Krishan Maggon 's insight:
Swisher, J. F. A. and Feldman, G. M. (2015), The many faces of FcγRI: implications for therapeutic antibody function. Immunol Rev, 268: 160–174. doi:10.1111/imr.12334
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Recently, we demonstrated that IgG Abs can organize into ordered hexamers after binding their cognate Ags expressed on cell surfaces. This process is dependent on Fc:Fc interactions, which promote C1q binding, the first step in classical pathway complement activation. We went on to engineer point mutations that stimulated IgG hexamer formation and complement-dependent cytotoxicity (CDC). The hexamer formation–enhanced (HexaBody) CD20 and CD38 mAbs support faster, more robust CDC than their wild-type counterparts. To further investigate the CDC potential of these mAbs, we used flow cytometry, high-resolution digital imaging, and four-color confocal microscopy to examine their activity against B cell lines and primary chronic lymphocytic leukemia cells in sera depleted of single complement components. We also examined the CDC activity of alemtuzumab (anti-CD52) and mAb W6/32 (anti-HLA), which bind at high density to cells and promote substantial complement activation. Although we observed little CDC for mAb-opsonized cells reacted with sera depleted of early complement components, we were surprised to discover that the Hexabody mAbs, as well as ALM and W6/32, were all quite effective at promoting CDC in sera depleted of individual complement components C6 to C9. However, neutralization studies conducted with an anti-C9 mAb verified that C9 is required for CDC activity against cell lines. These highly effective complement-activating mAbs efficiently focus activated complement components on the cell, including C3b and C9, and promote CDC with a very low threshold of MAC binding, thus providing additional insight into their enhanced efficacy in promoting CDC.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Science & Innovation: Science 101 - The Power of Proteins

Science & Innovation: Science 101 - The Power of Proteins | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Science 101: The Power of Proteins

When trying to develop protein replacement treatments, scientists often engineer the therapeutic protein as an optimized, improved version [...] Food and Drug Administration (FDA) has not yet approved any gene therapy for use in the United States, but many research projects are focused on developing such techniques for use in patients [...] 000Scoop.it! Nursing Supervisor at St. Helena Hospital Scoop.it Smart Suggestion Engine www.healthcaresource.com - August 19 [...] 
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New flu strains and old antibodies: How sinful is 'original antigenic sin'?

New flu strains and old antibodies: How sinful is 'original antigenic sin'? | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Immune memory ensures a quick, specific response to previously encountered pathogens.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Paris, France and Tarrytown, New York – August 29, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p<0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
Krishan Maggon 's insight:
About Praluent 

Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which results in lower LDL cholesterol levels in the blood. Praluent is the only PCSK9 inhibitor available in two dosages with two levels of efficacy (75 mg and 150 mg), allowing physicians to select dose based on a patient’s LDL cholesterol lowering needs. 

Praluent is approved in approximately 40 countries worldwide, including the U.S., Japan, Canada, Switzerland, Mexico, Brazil and the European Union (EU). In the U.S., Praluent is approved for use as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic CV disease, who require additional lowering of LDL cholesterol. In the E.U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL cholesterol goals with the maximally-tolerated statin or b) alone or in combination with other lipid-lowering therapies for patients who are statin intolerant, or for whom a statin is contraindicated. The effect of Praluent on CV morbidity and mortality has not yet been determined. ODYSSEY OUTCOMES is prospectively evaluating the effect of Praluent on the occurrence of CV events in approximately 18,000 patients who have experienced an acute coronary syndrome.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Top 10 Best-selling Biologicals of 2015

Top 10 Best-selling Biologicals of 2015 | Top Selling Monoclonal Antibodies 2014 | Scoop.it
The European Biotech News Website

The top ten list has 7 monoclonal antibodies led by Humira which is the top selling medicinal brand with sales of $14 billion, 2 insulins Lantus and NovoRapid and Prevnar vaccine. 
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

European Commission Grants Orphan Drug Designation to Alexion ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)

European Commission Grants Orphan Drug Designation to Alexion ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD) | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hydrogen Deuterium Exchange Mass Spectrometry in Biopharmaceutical Discovery and Development – A Review

Hydrogen Deuterium Exchange Mass Spectrometry in Biopharmaceutical Discovery and Development – A Review | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Hydrogen Deuterium Exchange Mass Spectrometry in Biopharmaceutical Discovery & Development #mAbs #biosimilars #ADCs
https://t.co/aq6bZyG68W
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CTLA-4/CD152 - MMab - Bio SB

CTLA-4/CD152 - MMab - Bio SB | Top Selling Monoclonal Antibodies 2014 | Scoop.it
https://t.co/ypKlcapZcH
CTLA-4 proteína y gen, en linfocitos T citotóxicos.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus | Top Selling Monoclonal Antibodies 2014 | Scoop.it
- Regeneron Pharmaceuticals, Inc. (NASDAQ: <b>REGN</b>) today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS). 
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab)

European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab) | Top Selling Monoclonal Antibodies 2014 | Scoop.it

First Intravenous Anti-IL-5 Biologic Therapy for Severe Eosinophilic
Asthma Now Approved in Europe


 JERUSALEM--(BUSINESS WIRE)--Aug. 18, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the European Commission has granted marketing authorization for CINQAERO® (reslizumab) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. CINQAERO® is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.


Krishan Maggon 's insight:
CINQAERO® is expected to become commercially available to patients in Europe, by prescription, within the coming months. CINQAERO® is currently approved and marketed in the United States and Canada as CINQAIR® (reslizumab) Injection with pending regulatory approvals in other global markets.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity - Foss - 2015 - Immunological Reviews - Wiley Online Library

TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity - Foss - 2015 - Immunological Reviews - Wiley Online Library | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Summary Antibodies are key molecules in the fight against infections. Although previously thought to mediate protection solely in the extracellular environment, recent research has revealed that antibody-mediated protection extends to the cytosolic compartment of cells. This postentry viral defense mechanism requires binding of the antibody to a cytosolic Fc receptor named tripartite motif containing 21 (TRIM21). In contrast to other Fc receptors, TRIM21 shows remarkably broad isotype specificity as it does not only bind IgG but also IgM and IgA. When viral pathogens coated with these antibody isotypes enter the cytosol, TRIM21 is rapidly recruited and efficient neutralization occurs before the virus has had the time to replicate. In addition, inflammatory signaling is induced. As such, TRIM21 acts as a cytosolic sensor that engages antibodies that have failed to protect against infection in the extracellular environment. Here, we summarize our current understanding of how TRIM21 orchestrates humoral immunity in the cytosolic environment.
Krishan Maggon 's insight:
Foss, S., Watkinson, R., Sandlie, I., James, L. C. and Andersen, J. T. (2015), TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev, 268: 328–339. doi:10.1111/imr.12363
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Fc Receptors: Introduction - Hogarth - 2015 - Immunological Reviews - Wiley Online Library

Fc Receptors: Introduction - Hogarth - 2015 - Immunological Reviews - Wiley Online Library | Top Selling Monoclonal Antibodies 2014 | Scoop.it
The biological, medical, and industrial interest in FcR and antibody function has been focused mostly on FcR of nucleated leukocytes. However, there are two specific and important areas that have somewhat been neglected but are coming into prominence. Qiao et al. [27] highlight aspects of the uniquely primate FcγRIIa and its biochemistry and function that have been revealed by studies of the platelet. They review the roles of platelet FcγRIIa in injury, infection, and in autoimmunity and life-threatening HIT – a truly FcγR-dependent pathology – and suggest diagnostic strategies for HIT detection based on analysis of HIT patient plasma. The second area is the expression of canonical Type I FcR on non-hematopoietic cells. Anderson et al. [28] provide a perspective on non-hemopoietic expression of the inhibitory FcγRIIb. Its expression in liver endothelial cells makes this one of the most abundantly expressed receptors and, ironically, in cells that are not directly related to the immune system. The authors pose interesting questions for understanding the inhibitory FcR biology in the absence of ITAM-dependent immunoreceptor signaling. They raise the possibility of new pathways of FcR function in non-hemopoietic cells which may pose opportunities for antibody engineers and new challenges for regulatory authorities.
Krishan Maggon 's insight:
Hogarth, P. M. (2015), Fc Receptors: Introduction. Immunol Rev, 268: 1–5. doi:10.1111/imr.12372
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity - Cervenak - 2015 - Immunological Reviews - Wiley Online L...

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity - Cervenak - 2015 - Immunological Reviews - Wiley Online L... | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Abstract In recent years, there has been an increasing demand for the development of faster and more efficient technologies for the generation of monoclonal antibodies against challenging targets that are weakly immunogenic or available only in limited amounts. Typical classes of such targets are cell surface antigens such as G-protein related receptors (GPCRs) or ion channels. We have developed transgenic (Tg) mice and rabbits that overexpress the neonatal Fc receptor (FcRn), resulting in an augmented humoral immune response even if challenging antigens are used for immunization. The impressively enhanced FcRn-mediated immune reactions are characterized by improved IgG protection and enhanced antigen presentation leading to greater number of antigen-specific T-helper and B-cell activation in lymphoid organs. Notably, these animals do not show any sign of autoimmunity and can be efficiently bred. FcRn overexpression thus leads to a number of practical benefits for improved generation of monoclonal and polyclonal antibodies against multiple antigens, including weakly immunogenic epitopes or tiny amounts of proteins. This review summarizes our current understanding about the mechanisms by which FcRn overexpression leads to such a significantly enhanced humoral immune response.

KEYWORDS: B-cell activation; antigen presentation; monoclonal and polyclonal antibody generation; neonatal Fc receptor 

PMID: 26497527 DOI: 10.1111/imr.12364
Krishan Maggon 's insight:
Immunol Rev. 2015 Nov;268(1):269-87. doi: 10.1111/imr.12364. 

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity. 

Cervenak J1, Kurrle R2, Kacskovics I1,3.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. - PubMed - NCBI

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. - PubMed - NCBI | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Ther Clin Risk Manag. 2016 Aug 1;12:1161-70. doi: 10.2147/TCRM.S96720. eCollection 2016. Review

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal disorder resulting from somatic mutation in the PIG-A gene leading to a deficiency of the membrane-anchoring molecule glycosylphosphatidylinositol. The lack of expression of two glycosylphosphatidylinositol-anchored proteins involved in the regulation of the complement system renders PNH erythrocytes susceptible to complement-mediated lysis. Clinical manifestations include thromboembolic disease, chronic kidney injury, pulmonary hypertension, smooth muscle dysfunction, and chronic hemolysis. Until recently, treatment was mainly supportive with most patients suffering from significant morbidity and shortened survival compared to age-matched controls. The development of eculizumab, a humanized monoclonal antibody directed against the terminal complement protein C5, has resulted in dramatic improvements of survival and reduction in complications. In this paper, we review some special considerations pertaining to the use of eculizumab for PNH. 

KEYWORDS: GPI; MDS; anemia; hemolysis; somatic mutation; survival 

PMID: 27536121 DOI: 10.2147/TCRM.S96720
Krishan Maggon 's insight:
Ther Clin Risk Manag. 2016 Aug 1;12:1161-70. 
doi: 10.2147/TCRM.S96720. eCollection 2016. 

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. 

Al-Ani F1, Chin-Yee I1, Lazo-Langner A2.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

c-Fos Antibody

c-Fos Antibody | Top Selling Monoclonal Antibodies 2014 | Scoop.it
Mouse Monoclonal c-Fos Antibody. c-Fos plays an important role in many cellular functions, and is over-expressed in variety of cancers. Applications: ICC; IF; IHC; WB. Species Reactivity: H; M; R
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

This New Tuberculosis Drug Could Change the World

This New Tuberculosis Drug Could Change the World | Top Selling Monoclonal Antibodies 2014 | Scoop.it
A new weapon against a deadly infectious disease.

Which is why Sirturo, a drug discovered by Johnson & Johnson JNJ 0.00% in 2004 and given lightening fast approval by the FDA in December 2012, is such a big deal. The first-ever medicine approved for MDR-TB—and the first TB drug in four decades—J&J is now working with governments, physicians, and NGOs to spread the precious drug to those who need it. It’s not a blockbuster, but Sirturo is saving lives: the drug, which was added to the World Health Organization’s Essential Medicines List in 2015, has been registered in over 40 countries and used to treat more than 10,000 patients. Dr. Iqbal Master, who heads up TB care at King Dinuzulu Hospital in Durban, South Africa says Sirturo, which is used in conjunction with other meds, has “increased treatment success” in the most resistant patients.
Krishan Maggon 's insight:
Tuberculosis is an often overlooked scourge. Though it is preventable and curable, TB still kills 1.5 million people per year—300,000 more than are lost to AIDS annually—and rates as the world’s most deadly infectious disease. Thornier still is the proliferation of its drug-resistant forms (MDR- and XDR-TB) which—just as contagious, but harder to treat—have undermined global progress towards eradicating the disease. Half a million people develop drug-resistant TB each year; a UK parliamentary group in 2015 projected it will kill 75 million and cost the world $16.7 trillion over the next 35 years. Which is why Sirturo, a drug dis
more...
No comment yet.